About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNNCT04560582

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.

Lead sponsor: University of Minnesota•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Minnesota

This is an observational cohort study collecting data and blood specimens at designated time points. The primary outcome will be comparing the cPRA in patients that have a rise in cf-DNA to those that do not have a rise in cf-DNA. Seondary outcomes include comparison of the combined incidence of need for transfusion, need for methylprednisolone and allograft nephrectomy, ESA dose, allograft tenderness, and gross hematuria.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Failed allograft requiring dialysis
•No living donor available for re-transplant option or anticipated deceased donor within the next 12 months
•Patient to be enrolled prior to 3rd HD (hemodialysis) session or within 1 week of starting peritoneal dialysis

Exclusion Criteria

•17 years or younger
•cPRA at entrance of 100%
•Primary non-function of the allograft
•Multi-organ transplant

Related studies

Double Voiding and Post-transplant UTI

NCT05711446 · Urinary Tract Infections, Kidney Transplant; Complications

Vascular Complications After Kidney Transplantation

NCT07531966 · Kidney Transplant Recipient, Kidney Transplant; Complications, and more

RECRUITINGPhase 2

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

NCT06059664 · Kidney Transplant; Complications

RECRUITINGPhase 3

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

NCT05325008 · BK Viremia, Kidney Transplant Infection, and more

RECRUITINGPhase 2/3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470 · Kidney Transplant Rejection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 29, 2023Terms

Trial snapshot

StatusWITHDRAWN

Phase—

Enrollment—

Start dateSep 2022

Last updatedNov 29, 2023

Condition

Kidney Transplant; Complications Kidney Transplant Rejection Kidney Transplant Failure

Locations shown

University of Minnesota

Minneapolis, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 29, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions